Home Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
 

Keywords :   


Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

2014-11-17 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data today american primary

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »